Active, not recruitingPhase 3NCT05059262
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
Studying Tenosynovial giant cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Deciphera Pharmaceuticals, LLC
- Intervention
- Vimseltinib(drug)
- Enrollment
- 123 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- City of Hope, Duarte, California, United States
- UC Davis Comprehensive Cancer Center, Sacramento, California, United States
- University of Colorado, Aurora, Colorado, United States
- University of Kansas, Kansas City, Kansas, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Mayo Clinic Rochester, Rochester, Minnesota, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Duke Sarcoma Research, Durham, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Seattle Cancer Care Alliance, Seattle, Washington, United States
- Chris O'Brien Lifehouse, Camperdown, Australia
- McGill University, Montreal, Canada
- Princess Margaret Hospital, Toronto, Canada
- Institut Bergonié, Bordeaux, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05059262 on ClinicalTrials.govOther trials for Tenosynovial giant cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07499362Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- RECRUITINGPHASE4NCT07315841Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor SurgeryShanghai Jiao Tong University Affiliated Sixth People's Hospital
- RECRUITINGNCT07075471Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With VimseltinibDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE3NCT05417789Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)SynOx Therapeutics Limited
- ACTIVE NOT RECRUITINGPHASE3NCT05804045Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Abbisko Therapeutics Co, Ltd
- ACTIVE NOT RECRUITINGPHASE2NCT04703322A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanDaiichi Sankyo Co., Ltd.
- RECRUITINGNCT04635111A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) TreatmentDaiichi Sankyo
- ACTIVE NOT RECRUITINGPHASE3NCT04488822A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTDaiichi Sankyo Co., Ltd.